UTI INDIA INNOVATION FUND

Institutional Accumulating Class (EUR) as of 30th June, 2026

uti Investments

Investment Objective

The investment objective of the Sub-Fund is to achieve medium to long-term returns through investment primarily in growth and innovation oriented Indian stocks which are already listed or soon to be listed on a Recognised Exchange.

Risk And Reward Profile

Potentially Lower Rewards — Potentially Higher Rewards

1	2	3	4	5	6	7

Net Performance Analysis*

NAV Per Share	10.27
52 wk high	12.21
52 wk low	8.39
Fund Size (USD Mil)	36.21
No of holdings	31

Source: Morningstar Direct & UTI IS. Performance of over one year is annualised.

*Returns may increase or decrease as a result of currency fluctuations

(in EUR %)	1 Month	3 Months	6 Months	1 Year	3 Years	Since Inception
UTI India Innovation EUR Instl Acc	4.39	22.39	-7.77	-15.00	-1.33	0.75
NIFTY 500 TR INR	4.19	13.50	-5.59	-8.57	6.00	5.08
Relative Performance	0.20	8.89	-2.18	-6.43	-7.33	-4.33

(in EUR %)	YTD	2025	2024	2023
UTI India Innovation EUR Instl Acc	-7.77	-24.13	23.25	29.64
Nifty 500 TR INR	-5.59	-9.50	20.53	21.90
Relative Performance	-2.18	-14.63	2.72	7.74

Calculation Benchmark: NIFTY 500 TR INR

Calculation Benchmark is converted to the currency of the share class

Time Period: 21/11/2022 - 30/06/2026



Fund Information

Investment Manager	UTI International (Singapore) Pvt. Ltd.
Investment Advisor	UTI Asset Management Co Ltd
Domicile	Ireland
Fund Regulations	UCITS
EU SFDR Classification	Article 8

Inception Date	18-11-2022
ISIN	IE0001APTX67
BBG Ticker	UTGFPIT ID
BBG FIGI	BBG017CS5KZ0
Management Fee	0.80%
Min. Initial Subscription	EUR 500,000
Min. Subsequent Transaction	EUR 50,000

Registered In	Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, Ireland, Italy, Luxembourg, Netherlands, Norway, Singapore, Sweden
Administrator	Citibank Europe PLC
Custodian	Citi Depositary Services Ireland Limited
Auditor	Ernst & Young (Dublin)

Note: Shareholders may be subject to a maximum sales charge of up to 5% of the subscription amount. Such sales charge will be charged as a preliminary oneoff charge, payable to the Distributor upon subscription. The Distributor may, in its sole discretion, waive or reduce, in whole or in part, any of such charge.

Portfolio Information



Top Ten Equity Holdings

Eternal Ltd	9.32%
Info Edge (India) Ltd	7.45%
FSN E-Commerce Ventures Ltd	5.49%
Affle 3i Ltd	5.30%
Acutaas Chemicals Ltd	5.27%
One97 Communications Ltd	4.81%
Rategain Travel Technologies Ltd	4.77%
Delhivery Ltd	4.17%
PB Fintech Ltd	4.00%
MTAR Technologies Ltd	3.81%

Market Capitalisation

Large Cap	16.77%
Mid Cap	24.53%
Small Cap	56.11%
Cash & Equivalents	2.59%

UTI INDIA INNOVATION FUND

Important Legal Information

This is a marketing communication. Please refer to the Prospectus and KIID of the fund before making any final investment decisions.
This material contains information relating to the sub-funds of UTI Goldfinch Funds Plc (the "Company") which is authorised by the Central Bank of Ireland as an open-ended investment company with variable capital and segregated liability between its sub-funds, established as an undertaking for collective investment in transferrable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011) as amended in Ireland with different classes of shares.

The Company makes no representation with regard to the completeness and accuracy of the data or information contained herein, and it accepts no responsibility and disclaims all liability for loss or damage whatsoever suffered or incurred by any other person resulting from the use of, or reliance upon, the data or information contained herein. We recommend that you obtain detailed information before making any investment decision on the basis of the Prospectus, key information document (PRIIPs KID) and key investor information document (UCITS KIID) – as appropriate for your relevant jurisdiction, along with other fund related materials free of charge from https://utifunds.com.

These documents can also be obtained from our centralised facilities agent, DE Facilities Limited, 33 Sir John Rogerson's Quay, Dublin 2, Ireland or the following paying agents/distributors: **France** – CACEIS Bank, located at 1-3, Place Valhubert Paris Cedex 13, 75206 France; **Italy** – Allfunds Bank, Via Bocchetto, 6, 20123 Milano, Italy ; **Spain** – Banco Inversis, S.A., Avda de la Hispanidad, 6, 28042 Madrid ; **Switzerland** – CACEIS Investor Services Bank S.A., Esch-sur-Alzette, Zurich Branch, Bleicherweg 7, CH-8027 Zurich, Switzerland ; and **United Kingdom** – UTI International Limited, 120 New Cavendish Street, London W1W 6XX, United Kingdom.

Please note in addition for:

France: The Fund has been authorised for sale in France by the Autorité des Marchés financiers. The centralising correspondent in France is CACEIS Bank, located at 1-3, Place Valhubert Paris Cedex 13, 75206 France. Investors should note that, relative to the expectations of the Autorité des Marchés financiers, this (UCITS) presents reduced communication on the consideration of non-financial criteria in its management. Past performance mentioned herein is/are not necessarily indicative of future performance. The information referred to in this communication does not consider particular investment objectives, financial situations or specific needs of individual clients. This communication does not constitute an offer of financial instruments of any kind whatsoever and cannot be considered as solicitation with a view to buying or selling such financial products. UTI International France SAS does not guarantee or assume any responsibility for the information contained in this communication, which is produced by UTI International Singapore Private Ltd, whether for its accuracy, completeness or precision. Investments may result in total or partial loss of capital. This material is intended for professional investors only. We have implemented robust internal mechanisms to prevent conflicts of interest in investment recommendations and advice. No conflicts of interest were identified in the publication of this document. Redistribution of this document, either in whole or in part, is prohibited without prior consent.

Italy: The Fund has been registered with the Commissione Nazionale per le Società e la Borsa (CONSOB) for the offer to both Professional Investors and Retail Investors (as defined in applicable CONSOB regulations). For retail distribution, the offering of the Fund can only be carried out by the appointed distributor (and their approved sub-distributors) as indicated in the Italian subscription form (Modulo di Sottoscrizione) in accordance with the procedures indicated therein. Retail investors in Italy may confer on the Italian Paying Agent a specific mandate empowering the latter to act in its own name and on behalf of the same investors. Under this mandate, the Italian Paying Agent in its own name and on behalf of the investors in Italy shall (i) transmit in aggregated form to the Fund on subscription /redemption/conversion orders; (ii) hold the Shares in the register of shareholders of the Fund and (iii) carry out any other administrative activity under the investment contract. Further details of such mandate are provided for in the Italian subscription form. Regular Savings Plans, redemption and switch programmes are available in Italy via the Italian paying agent. In addition to the fees and expenses indicated in the fund Prospectus, Italian investors are charged fees relating to paying agent. Further information on Regular Savings Plans and paying agent fees is provided in the Italian subscription form. The distributor and local paying agent in Italy is Allfunds Bank, Via Bocchetto, 6, 20123 Milano, Italy. The legal documents of the Fund can be obtained free of charge upon request from the local paying agent.

Singapore: The Fund is a recognised scheme under the Securities and Futures Act, Chapter 289 of Singapore ("SFA"). A copy of the Singapore Prospectus has been lodged with and registered by the Monetary Authority of Singapore ("MAS"). This advertisement has not been reviewed by MAS. Investors from Singapore must read the Singapore prospectus and the product highlights sheet before making any investment decision. The MAS assumes no responsibility for the contents of the Singapore Prospectus. Registration of the Singapore Prospectus by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with. The MAS has not, in any way, considered the investment merits of the Company. The distribution of this Singapore Prospectus and the offering or sale of the Shares in the Company in some jurisdictions may be restricted or prohibited. Persons who have possession of the Singapore Prospectus of the Fund must inform themselves about and observe such restrictions or prohibitions.

United States: This document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the United States or any province or territory thereof, where none of the Fund or the Shares are authorised or registered for distribution and where no prospectus of the Fund has been filed with any securities commission or regulatory authority. Neither this document nor any copy hereof should be taken, transmitted or distributed (directly or indirectly) into the United States. Neither the Fund or any of the Shares have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

Other jurisdictions: The distribution of this document of the Fund or Prospectus of the Fund and the offering of Shares of the Fund may be restricted in certain jurisdictions. This document or the Prospectus of the Fund does not constitute an offer or solicitation in any jurisdiction in which such offer or solicitation is not authorised or the person receiving the offer or solicitation may not lawfully do so. It is the responsibility of any person in possession of this document or the Prospectus of the Fund and of any person wishing to apply for Shares of the Fund to inform himself of and to observe all applicable laws and regulations of the countries of his nationality, residence, ordinary residence or domicile.

United Arab Emirates: The information on the list of licensed distributors for this fund will be available from the investment manager of the Fund. This document is being communicated by the UTI International (Singapore) Private Limited - DIFC Branch (which is regulated by Dubai Financial Services Authority (DFSA)). This material is intended only for Professional clients and Market counterparties as defined by the DFSA and no other person should act upon it. This document relates to a financial product which is not subject to any form of regulation or approval by the DFSA. The DFSA has no responsibility for reviewing or verifying any prospectus or other documents in connection with this financial product. Accordingly, the DFSA has not approved this document, or any other associated documents not taken any steps to verify the information set out in this document and has no responsibility for it. The financial product to which this document relates may be illiquid and/or subject to restrictions on its resale. Prospective purchases should conduct their own due diligence on the financial product. If you do not understand the contents of this document, you should consult an authorised financial adviser.